Symbols / FEMY $0.60 -3.75%
FEMY Chart
About
Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs in the United States and internationally. The company offers FemaSeed, an intratubal insemination solution; FemVue, a companion diagnostic for fallopian tube assessment through ultrasound; FemCerv, an endocervical tissue sampler for cervical cancer diagnosis; FemCath, a cornual balloon catheter for selective fallopian tube evaluation; and FemChec, a controlled contrast-generating device for fallopian tube diagnosis. It also develops FemBloc, a non-surgical permanent birth control solution. The company offers its products to reproductive endocrinologists, gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Medical Instruments & Su | Market Cap | 35.42M |
| Enterprise Value | 39.96M | Income | -19.80M | Sales | 2.06M |
| Book/sh | 0.10 | Cash/sh | 0.08 | Dividend Yield | — |
| Payout | 0.00% | Employees | 69 | IPO | — |
| P/E | — | Forward P/E | -1.51 | PEG | — |
| P/S | 17.18 | P/B | 6.20 | P/C | — |
| EV/EBITDA | -2.30 | EV/Sales | 19.38 | Quick Ratio | 0.49 |
| Current Ratio | 1.16 | Debt/Eq | 184.96 | LT Debt/Eq | — |
| EPS (ttm) | -0.69 | EPS next Y | -0.40 | EPS Growth | — |
| Revenue Growth | 31.40% | Earnings | 2025-11-14 16:00 | ROA | -69.37% |
| ROE | -3.76% | ROIC | — | Gross Margin | 63.05% |
| Oper. Margin | -5.01% | Profit Margin | 0.00% | Shs Outstand | 59.50M |
| Shs Float | 48.79M | Short Float | 3.81% | Short Ratio | 3.81 |
| Short Interest | — | 52W High | 1.76 | 52W Low | 0.31 |
| Beta | -2.53 | Avg Volume | 933.43K | Volume | 294.58K |
| Target Price | $3.67 | Recom | Buy | Prev Close | $0.62 |
| Price | $0.60 | Change | -3.75% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$3.67
Mean price target
2. Current target
$0.60
Latest analyst target
3. DCF / Fair value
$-3.82
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.60
Low
$1.50
High
$6.50
Mean
$3.67
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-03 | init | Lake Street | — → Buy | $2 |
| 2025-11-20 | init | Laidlaw & Co. | — → Buy | $7 |
| 2025-08-11 | main | HC Wainwright & Co. | Buy → Buy | $8 |
| 2025-06-25 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2025-06-11 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2025-05-13 | main | Jones Trading | Buy → Buy | $6 |
| 2025-05-09 | main | HC Wainwright & Co. | Buy → Buy | $12 |
| 2025-03-28 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2025-03-19 | main | HC Wainwright & Co. | Buy → Buy | $15 |
| 2025-03-18 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2025-03-13 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2025-02-26 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2025-02-11 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2024-12-03 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2024-11-27 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2024-11-13 | main | Chardan Capital | Buy → Buy | $8 |
| 2024-11-12 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2024-10-31 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2024-09-12 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2024-08-14 | main | Chardan Capital | Buy → Buy | $10 |
- New non-surgical permanent birth control clears key global quality hurdle - Stock Titan hu, 26 Feb 2026 08
- Femasys begins enrollment in pivotal trial for FemBloc device - Investing.com Nigeria ue, 17 Mar 2026 01
- Femasys files to sell 68.42M shares of common stock for holders - MSN Mon, 16 Mar 2026 12
- Femasys (FEMY) Falls 27% as Firm to Raise $8-Million from Share Sale - Yahoo Finance Wed, 27 Aug 2025 07
- Femasys Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire Fri, 27 Feb 2026 08
- New Analyst Forecast: $FEMY Given $6.5 Price Target - Quiver Quantitative hu, 20 Nov 2025 08
- Femasys Stock Drop Looks Sharp, But How Deep Can It Go? - Trefis ue, 23 Dec 2025 08
- Non-surgical permanent birth control FemBloc begins final U.S. trial - Stock Titan ue, 10 Mar 2026 13
- Femasys Inc. Advances FemBloc Toward FDA Approval with Successful Trial Completion and $12 Million Financing - Quiver Quantitative Mon, 03 Nov 2025 08
- Nasdaq gives Femasys more time to fix sub-$1 share price by July 2026 - Stock Titan Wed, 14 Jan 2026 08
- AMA procedure code supports new infertility option for over 10M US women - Stock Titan Mon, 23 Feb 2026 08
- New device could make fallopian tube testing simpler for fertility care - Stock Titan hu, 18 Dec 2025 08
- PharmaCyte Biotech (Nasdaq: PMCB) Now Holds ~$20M Cash, $25M in Marketable Securities - Stock Titan ue, 25 Nov 2025 08
- Femasys (FEMY) CEO awarded 729,000 RSUs vesting through 2027 - Stock Titan Fri, 20 Feb 2026 08
- Femasys (NASDAQ: FEMY) announces $500K second order for FemBloc in France & Benelux - Stock Titan Mon, 10 Nov 2025 08
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.21 | 0.27 |
| NormalizedEBITDA | -16.33M | -13.17M | -10.49M | -6.55M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -18.82M | -14.25M | -11.39M | -7.54M |
| ReconciledDepreciation | 872.00K | 907.99K | 889.14K | 964.29K |
| ReconciledCostOfRevenue | 544.90K | 380.07K | 114.03K | 370.38K |
| EBITDA | -16.33M | -13.17M | -10.49M | -6.55M |
| EBIT | -17.20M | -14.08M | -11.37M | -7.51M |
| NetInterestIncome | -1.02M | 265.63K | 214.70K | -15.46K |
| InterestExpense | 1.60M | 165.39K | 13.46K | 19.23K |
| InterestIncome | 582.35K | 431.02K | 228.16K | 3.77K |
| NormalizedIncome | -18.82M | -14.25M | -11.39M | -7.54M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -18.82M | -14.25M | -11.39M | -7.54M |
| TotalExpenses | 19.41M | 15.58M | 12.81M | 9.52M |
| TotalOperatingIncomeAsReported | -17.79M | -14.51M | -11.60M | -8.34M |
| DilutedAverageShares | 22.27M | 15.38M | 11.82M | 6.71M |
| BasicAverageShares | 22.27M | 15.38M | 11.82M | 6.71M |
| DilutedEPS | -0.85 | -0.93 | -0.96 | -1.12 |
| BasicEPS | -0.85 | -0.93 | -0.96 | -1.12 |
| DilutedNIAvailtoComStockholders | -18.82M | -14.25M | -11.39M | -7.54M |
| NetIncomeCommonStockholders | -18.82M | -14.25M | -11.39M | -7.54M |
| NetIncome | -18.82M | -14.25M | -11.39M | -7.54M |
| NetIncomeIncludingNoncontrollingInterests | -18.82M | -14.25M | -11.39M | -7.54M |
| NetIncomeContinuousOperations | -18.82M | -14.25M | -11.39M | -7.54M |
| TaxProvision | 9.60K | 4.34K | 6.30K | 4.00K |
| PretaxIncome | -18.81M | -14.24M | -11.39M | -7.53M |
| OtherIncomeExpense | -2.31K | 818.42K | ||
| OtherNonOperatingIncomeExpenses | -2.31K | 818.42K | ||
| NetNonOperatingInterestIncomeExpense | -1.02M | 265.63K | 214.70K | -15.46K |
| InterestExpenseNonOperating | 1.60M | 165.39K | 13.46K | 19.23K |
| InterestIncomeNonOperating | 582.35K | 431.02K | 228.16K | 3.77K |
| OperatingIncome | -17.79M | -14.51M | -11.60M | -8.34M |
| OperatingExpense | 18.87M | 15.20M | 12.36M | 9.15M |
| DepreciationAmortizationDepletionIncomeStatement | 297.32K | 483.48K | 561.23K | 591.07K |
| DepreciationAndAmortizationInIncomeStatement | 297.32K | 483.48K | 561.23K | 591.07K |
| ResearchAndDevelopment | 8.22M | 7.21M | 5.81M | 4.08M |
| SellingGeneralAndAdministration | 10.36M | 7.51M | 5.99M | 4.47M |
| SellingAndMarketingExpense | 4.03M | 650.13K | 558.85K | 208.74K |
| GeneralAndAdministrativeExpense | 6.33M | 6.86M | 5.43M | 4.26M |
| OtherGandA | 6.33M | 6.86M | 5.43M | 4.26M |
| GrossProfit | 1.08M | 691.90K | 764.28K | 809.30K |
| CostOfRevenue | 544.90K | 380.07K | 441.94K | 370.38K |
| TotalRevenue | 1.63M | 1.07M | 1.21M | 1.18M |
| OperatingRevenue | 1.63M | 1.07M | 1.21M | 1.18M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TreasurySharesNumber | 117.22K | 117.22K | 117.22K | 117.22K |
| OrdinarySharesNumber | 23.36M | 21.66M | 11.87M | 11.80M |
| ShareIssued | 23.47M | 21.77M | 11.99M | 11.92M |
| NetDebt | 1.95M | |||
| TotalDebt | 7.44M | 6.70M | 543.72K | 1.01M |
| TangibleBookValue | 2.24M | 18.35M | 15.24M | 26.31M |
| InvestedCapital | 7.71M | 22.61M | 15.38M | 26.53M |
| WorkingCapital | -560.42K | 20.12M | 12.60M | 23.94M |
| NetTangibleAssets | 2.24M | 18.35M | 15.24M | 26.31M |
| CapitalLeaseObligations | 2.04M | 2.44M | 402.42K | 809.09K |
| CommonStockEquity | 2.30M | 18.35M | 15.24M | 26.33M |
| TotalCapitalization | 2.30M | 22.61M | 15.24M | 26.33M |
| TotalEquityGrossMinorityInterest | 2.30M | 18.35M | 15.24M | 26.33M |
| StockholdersEquity | 2.30M | 18.35M | 15.24M | 26.33M |
| OtherEquityInterest | 1.86M | 2.79M | 567.97K | 702.49K |
| GainsLossesNotAffectingRetainedEarnings | 0.00 | |||
| TreasuryStock | 60.00K | 60.00K | 60.00K | 60.00K |
| RetainedEarnings | -127.20M | -108.38M | -94.13M | -82.74M |
| AdditionalPaidInCapital | 127.68M | 123.99M | 108.86M | 108.42M |
| CapitalStock | 23.47K | 21.77K | 11.99K | 11.92K |
| CommonStock | 23.47K | 21.77K | 11.99K | 11.92K |
| PreferredStock | 0.00 | |||
| TotalLiabilitiesNetMinorityInterest | 10.14M | 9.40M | 1.65M | 2.24M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 1.56M | 6.35M | 125.24K | 552.21K |
| OtherNonCurrentLiabilities | 39.61K | 54.94K | 96.66K | 149.79K |
| PreferredSecuritiesOutsideStockEquity | 0.00 | |||
| LongTermDebtAndCapitalLeaseObligation | 1.52M | 6.29M | 28.58K | 402.42K |
| LongTermCapitalLeaseObligation | 1.52M | 2.04M | 28.58K | 402.42K |
| LongTermDebt | 4.26M | |||
| CurrentLiabilities | 8.58M | 3.05M | 1.53M | 1.69M |
| OtherCurrentLiabilities | 88.58K | 65.30K | 45.21K | 36.04K |
| CurrentDebtAndCapitalLeaseObligation | 5.92M | 406.64K | 515.13K | 606.74K |
| CurrentCapitalLeaseObligation | 517.97K | 406.64K | 373.83K | 406.67K |
| CurrentDebt | 5.41M | 141.30K | 200.07K | |
| OtherCurrentBorrowings | 5.41M | 186.50K | 200.07K | |
| CurrentNotesPayable | 0.00 | 141.30K | ||
| PensionandOtherPostRetirementBenefitPlansCurrent | 650.77K | 1.08M | 85.19K | 98.27K |
| PayablesAndAccruedExpenses | 1.92M | 1.50M | 882.28K | 951.04K |
| CurrentAccruedExpenses | 500.28K | 349.53K | 344.64K | 402.50K |
| Payables | 1.42M | 1.15M | 537.64K | 548.54K |
| TotalTaxPayable | 0.00 | 12.16K | 26.89K | 103.02K |
| AccountsPayable | 1.42M | 1.14M | 510.76K | 445.52K |
| TotalAssets | 12.45M | 27.76M | 16.90M | 28.58M |
| TotalNonCurrentAssets | 4.42M | 4.58M | 2.76M | 2.95M |
| OtherNonCurrentAssets | 954.99K | 1.09M | 958.18K | 655.42K |
| GoodwillAndOtherIntangibleAssets | 65.92K | 0.00 | 3.29K | 25.09K |
| OtherIntangibleAssets | 65.92K | 3.29K | 25.09K | |
| NetPPE | 3.40M | 3.49M | 1.80M | 2.26M |
| AccumulatedDepreciation | -3.74M | -3.55M | -3.22M | -2.72M |
| GrossPPE | 7.14M | 7.04M | 5.02M | 4.99M |
| Leases | 1.24M | 1.21M | 1.20M | 1.16M |
| ConstructionInProgress | 762.45K | 423.08K | 413.84K | 379.71K |
| OtherProperties | 1.81M | 2.38M | 319.56K | 665.75K |
| MachineryFurnitureEquipment | 3.34M | 3.02M | 3.09M | 2.79M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 8.02M | 23.18M | 14.13M | 25.63M |
| OtherCurrentAssets | 1.04M | 695.88K | 655.36K | 555.85K |
| Inventory | 3.05M | 667.12K | 436.72K | 208.27K |
| FinishedGoods | 754.83K | 170.19K | 91.77K | 83.94K |
| WorkInProcess | 982.63K | 128.99K | 100.45K | 12.79K |
| RawMaterials | 1.31M | 367.93K | 244.50K | 111.53K |
| Receivables | 488.37K | 98.91K | 77.47K | 84.26K |
| AccountsReceivable | 488.37K | 98.91K | 77.47K | 84.26K |
| AllowanceForDoubtfulAccountsReceivable | -10.00K | -2.00K | -2.05K | -2.03K |
| GrossAccountsReceivable | 498.37K | 100.91K | 79.52K | 86.28K |
| CashCashEquivalentsAndShortTermInvestments | 3.45M | 21.72M | 12.96M | 24.78M |
| CashAndCashEquivalents | 3.45M | 21.72M | 12.96M | 24.78M |
| CashEquivalents | 3.45M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -20.29M | -11.42M | -11.14M | -8.24M |
| RepaymentOfDebt | 0.00 | -626.53K | -528.26K | -462.95K |
| IssuanceOfDebt | 0.00 | 6.85M | 0.00 | 0.00 |
| IssuanceOfCapitalStock | 2.03M | 11.56M | 59.58K | 31.74M |
| CapitalExpenditure | -847.76K | -143.92K | -407.48K | -306.87K |
| InterestPaidSupplementalData | 111.00K | 9.90K | 13.46K | 15.87K |
| IncomeTaxPaidSupplementalData | 5.71K | 4.55K | 5.05K | 800.00 |
| EndCashPosition | 3.45M | 21.72M | 12.96M | 24.78M |
| BeginningCashPosition | 21.72M | 12.96M | 24.78M | 3.32M |
| ChangesInCash | -18.26M | 8.75M | -11.82M | 21.46M |
| FinancingCashFlow | 2.03M | 20.18M | -681.64K | 29.70M |
| CashFlowFromContinuingFinancingActivities | 2.03M | 20.18M | -681.64K | 29.70M |
| NetOtherFinancingCharges | -60.75K | -1.30M | -232.84K | -1.58M |
| ProceedsFromStockOptionExercised | 63.11K | 3.69M | 19.88K | |
| NetCommonStockIssuance | 2.03M | 11.56M | 59.58K | 31.74M |
| CommonStockIssuance | 2.03M | 11.56M | 59.58K | 31.74M |
| NetIssuancePaymentsOfDebt | 0.00 | 6.22M | -528.26K | -462.95K |
| NetLongTermDebtIssuance | 0.00 | 6.22M | -528.26K | -462.95K |
| LongTermDebtPayments | 0.00 | -626.53K | -528.26K | -462.95K |
| LongTermDebtIssuance | 0.00 | 6.85M | 0.00 | 0.00 |
| InvestingCashFlow | -847.76K | -143.92K | -407.48K | -306.87K |
| CashFlowFromContinuingInvestingActivities | -847.76K | -143.92K | -407.48K | -306.87K |
| NetInvestmentPurchaseAndSale | 0.00 | |||
| SaleOfInvestment | 0.00 | |||
| NetIntangiblesPurchaseAndSale | -86.06K | 0.00 | 0.00 | |
| PurchaseOfIntangibles | -86.06K | 0.00 | 0.00 | |
| NetPPEPurchaseAndSale | -761.71K | -143.92K | -407.48K | -306.87K |
| PurchaseOfPPE | -761.71K | -143.92K | -407.48K | -306.87K |
| OperatingCashFlow | -19.44M | -11.28M | -10.73M | -7.93M |
| CashFlowFromContinuingOperatingActivities | -19.44M | -11.28M | -10.73M | -7.93M |
| ChangeInWorkingCapital | -3.14M | 1.23M | -458.27K | -732.72K |
| ChangeInOtherCurrentLiabilities | -443.20K | -417.59K | -446.53K | -439.20K |
| ChangeInOtherCurrentAssets | 295.86K | 475.99K | ||
| ChangeInPayablesAndAccruedExpense | 214.23K | 1.61M | -81.84K | -733.61K |
| ChangeInAccruedExpense | 6.75K | 987.58K | -147.07K | -504.80K |
| ChangeInPayable | 207.48K | 627.07K | 65.24K | -228.81K |
| ChangeInAccountPayable | 207.48K | 627.07K | 65.24K | -228.81K |
| ChangeInPrepaidAssets | -139.14K | 282.17K | 295.86K | |
| ChangeInInventory | -2.38M | -230.40K | -232.55K | -77.43K |
| ChangeInReceivables | -397.47K | -21.44K | 6.79K | 41.53K |
| ChangesInAccountReceivables | -397.47K | -21.44K | 6.79K | 41.53K |
| OtherNonCashItems | 1.19M | 107.96K | -821.51K | |
| StockBasedCompensation | 444.15K | 675.70K | 224.94K | 193.37K |
| ProvisionandWriteOffofAssets | 8.00K | 0.00 | 4.10K | 540.00 |
| AmortizationOfSecurities | 0.00 | |||
| DepreciationAmortizationDepletion | 872.00K | 907.99K | 889.14K | 964.29K |
| DepreciationAndAmortization | 872.00K | 907.99K | 889.14K | 964.29K |
| AmortizationCashFlow | 20.14K | 3.29K | 21.80K | 39.98K |
| AmortizationOfIntangibles | 20.14K | 3.29K | 21.80K | 39.98K |
| Depreciation | 851.86K | 904.69K | 867.34K | 924.31K |
| OperatingGainsLosses | 676.00 | 47.54K | 2.29K | -818.42K |
| GainLossOnSaleOfPPE | 676.00 | 47.54K | 2.29K | 3.10K |
| NetIncomeFromContinuingOperations | -18.82M | -14.25M | -11.39M | -7.54M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for FEMY
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|